Academic Health Center
Stay Connected
news-and-notes

University of Minnesota researchers find better time to start HIV therapy

Patients suffering from an AIDS-related infection should start therapy later than expected, according to a new study from the University of Minnesota Medical School.

In a report set to appear in the June 26, 2014, issue of the New England Journal of Medicine, researchers found that waiting 4-6 weeks to start HIV therapy after cryptococcal meningitis diagnosis resulted in 15% better survival than starting HIV therapy 1-2 weeks after diagnosis.

“The overall result is quite surprising. As with every other AIDS-related infection, starting HIV therapy sooner is better,” said the study’s lead author David Boulware, M.D., M.P.H. “It appears that brain infections are different.”

Read more
research-and-clinical-trials

Game Changer: Dominic Travis

In 2003, a team of scientists made a groundbreaking discovery tracing the origin of Human Immunodeficiency Virus (HIV) back to African monkeys. Since then, Dominic Travis, D.V.M.,has been at the forefront of a collaborative effort that seeks to fully understand how infectious diseases impact all primates — including humans.

“We try and find variables that connect habitat, wildlife, livestock and humans,” said Travis, wildlife veterinary medicine and epidemiology specialist at the U of M College of Veterinary Medicine.

Read more
research-and-clinical-trials

UMN, UNMC research shows persistent HIV replication is associated with lower drug concentrations in lymphatic tissues

Drugs used to treat HIV penetrate poorly into lymphatic tissues where most HIV replication takes place and there is persistent low-level virus replication in these tissues according to research from the University of Minnesota and University of Nebraska Medical Center.

“We know the drugs we use today are effective because our patients are doing better and living longer, but these drugs cannot cure the infection,” said Timothy Schacker, M.D., director of the Program in HIV Medicine at the University of Minnesota. “We wanted to know why and thought that maybe the drugs were not getting into the tissues where most virus replication is happening.”

Read more
research-and-clinical-trials

New anti-HIV drug target identified by University of Minnesota researchers

University of Minnesota researchers have discovered a first-of-its-kind series of compounds possessing anti-human immunodeficiency virus (HIV) activity. The compounds present a new target for potential HIV drug development and future treatment options.

Complete findings are printed in today’s issue of The Journal of Virology.

The compounds, known as ribonucleoside analogs 8-azaadenosine, formycin A, 3-deazauridine, 5-fluorocytidine and 2’-C-methylcytidine, were found to stop the replication and spread of HIV by blocking HIV DNA synthesis or by inducing lethal mutagenesis.

Read more
u-of-m-voices

A look forward on World AIDS Day 2013

Editor’s note: The following was adapted from a Program in Human Sexuality email authored by Eli Coleman to honor World AIDS Day 2013.

Medical advances, improved access to care, prevention initiatives, and our nation’s aspiration of an AIDS-free generation are all good signs, but as a culture we will need to shift our perspective to stop the spread of HIV.

Over the last 30 years, where have we failed?

Read more
research-and-clinical-trials

HIV protein may impact neurocognitive impairment in infected patients

A protein shed by HIV-infected brain cells alters synaptic connections between networks of nerve cells, according to new research out of the University of Minnesota. The findings could explain why nearly half of all patients infected with the AIDS virus experience some level of neurocognitive impairment.

Read more